1/8
08:17 am
ipsc
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes [Yahoo! Finance]
Medium
Report
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes [Yahoo! Finance]
1/8
08:00 am
ipsc
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes
High
Report
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes
1/8
06:15 am
ipsc
Century Therapeutics (NASDAQ:IPSC) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
High
Report
Century Therapeutics (NASDAQ:IPSC) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
12/9
08:00 am
ipsc
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
Medium
Report
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors
11/25
04:56 pm
ipsc
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
Medium
Report
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]
11/25
04:01 pm
ipsc
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
Low
Report
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
11/18
07:20 am
ipsc
Century Therapeutics (NASDAQ:IPSC) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
Low
Report
Century Therapeutics (NASDAQ:IPSC) was downgraded by analysts at Leerink Partnrs from a "strong-buy" rating to a "hold" rating.
11/17
08:06 am
ipsc
Century Therapeutics (NASDAQ:IPSC) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $2.00 price target on the stock, down previously from $7.00.
Low
Report
Century Therapeutics (NASDAQ:IPSC) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $2.00 price target on the stock, down previously from $7.00.
11/13
07:30 am
ipsc
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
High
Report
Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
11/13
07:00 am
ipsc
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
High
Report
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
10/20
01:04 am
ipsc
Century Therapeutics (NASDAQ:IPSC) was downgraded by analysts at
Wall St
Medium
Report
Century Therapeutics (NASDAQ:IPSC) was downgraded by analysts at
Wall St